Association of IGF-1 Levels With Height From Childhood to Adulthood: An Observational and Mendelian Randomization Study

What Was Tested

The paper reports a study of IGF-1 LR3, published as an observational study.

The researchers used two-sample Mendelian randomization (MR) to assess the causal effect of serum IGF-1 on adult height.

Who Took Part

The age groups tagged for this paper are children, teenagers and adults, both men and women.

Genetic instruments for IGF-1 were derived from a UK Biobank genome-wide association study (GWAS), and their effects on adult height were identified in the GIANT Consortium GWAS, excluding UK Biobank (Non-Hispanic White: N = 1 176 465; African descent: N = 168 191; South Asian: N = 49 032; East Asian: N = 361 369; Hispanic: N = 58 709).

Using the Avon Longitudinal Study of Parents and Children (ALSPAC), the researchers investigated cross-sectional and longitudinal associations between measured IGF-1 levels at ages 7 to 11 years or a genetic risk score (GRS) for IGF-1, with repeated height measurements at ages 7 to 17 years, adjusting for sex, body mass index (BMI), and pubertal stage.

What Was Measured

PubMed files the paper under topics including Insulin-Like Growth Factor I, Mendelian Randomization Analysis, Body Height, Genome-Wide Association Study, Cross-Sectional Studies, Longitudinal Studies and Polymorphism, Single Nucleotide.

The authors tagged it with the keywords ALSPAC and IGF-1.

What This Means in Plain Language

This is an observational study of IGF-1 LR3.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the IGF-1 LR3 compound page, all human trials.